Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutics (ZLD) receives formal approval from the German regulatory authority BfArM for the commercialisation of Zenivol in the country
- This is a significant milestone for the company as it allows Zelira to expand the availability of Zenivol beyond Australia for the first time
- Zenivol is a cannabinoid-based medicine used the treat chronic insomnia with a phase 1b/2a clinical trial showing it to be safe and effective
- According to Managing Director Dr Oludare Odumosu, the company is continuing to progress activities to licence Zenivol in other markets
- Shares in Zelira are up 13.1 per cent on market close, trading at $2.24 each
Zelira Therapeutics (ZLD) has received formal approval from the German regulatory authority BfArM for the commercialisation of Zenivol in the country.
This is a significant milestone for the company as it allows Zelira to expand the availability of Zenivol beyond Australia for the first time.
It also reinforces the pharmaceutical quality, safety and efficacy of Zenivol and Zelira’s other cannabinoid-based medicines.
Zenivol is a cannabinoid-based medicine used the treat chronic insomnia with a phase 1b/2a clinical trial showing it to be safe and effective.
“The formal approval of Zenivol by BfArM in Germany marks a major milestone for our business,” Managing Director Dr Oludare Odumosu commented.
“We look forward to working with our partner, Adjupharm in launching Zenivol in Germany and supporting patients and physicians in treating chronic insomnia in a safe and effective manner.
“With formal regulatory approval for Zenivol now received in Germany, we continue to progress activities to license Zenivol into other global markets.”
Shares in Zelira were up 13.1 per cent on market close and were trading at $2.24 each.
